Telomere Dysfunction and DNA Damage Checkpoints in Diseases and Cancer of the Gastrointestinal Tract

Gastroenterology

Volumn 137, Issue 3, 2009, Pages 754-762

  Rudolph, K Lenhard ^a   Hartmann, Daniel ^a,b   Opitz, Oliver G ^c  

^a UNIVERSITY OF ULM   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TELOMERASE;

AGING; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CHROMOSOME ABERRATION; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DNA DAMAGE; ENZYME ACTIVATION; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; TELOMERE DYSFUNCTION;

EID: 69249129156     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.07.037     Document Type: Article

References (78)

1. Kirkwood T.B. Understanding the odd science of aging. Cell 120 (2005) 437-447
2. Jiang H., Schiffer E., Song Z., et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A 105 (2008) 11299-11304
3. Blackburn E.H., and Gall J.G. A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena. J Mol Biol 120 (1978) 33-53
4. Moyzis R.K., Buckingham J.M., Cram L.S., et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 85 (1988) 6622-6626
5. Griffith J.D., Comeau L., Rosenfield S., et al. Mammalian telomeres end in a large duplex loop. Cell 97 (1999) 503-514
6. McElligott R., and Wellinger R.J. The terminal DNA structure of mammalian chromosomes. Embo J 16 (1997) 3705-3714
7. Allsopp R.C., Vaziri H., Patterson C., et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 89 (1992) 10114-10118
8. Wright W.E., and Shay J.W. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 27 (1992) 383-389
9. Nalapareddy K., Jiang H., Guachalla Gutierrez L.M., et al. Determining the influence of telomere dysfunction and DNA damage on stem and progenitor cell aging: what markers can we use?. Exp Gerontol 43 (2008) 998-1004
10. Brown J.P., Wei W., and Sedivy J.M. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277 (1997) 831-834
11. Stein G.H., Drullinger L.F., Soulard A., et al. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 19 (1999) 2109-2117
12. Lee H.W., Blasco M.A., Gottlieb G.J., et al. Essential role of mouse telomerase in highly proliferative organs. Nature 392 (1998) 569-574
13. Schaetzlein S., Kodandaramireddy N.R., Ju Z., et al. Exonuclease-1 deletion impairs DNA damage signaling and prolongs lifespan of telomere-dysfunctional mice. Cell 130 (2007) 863-877
14. Forsyth N.R., Morales C.P., Damle S., et al. Spontaneous immortalization of clinically normal colon-derived fibroblasts from a familial adenomatous polyposis patient. Neoplasia 6 (2004) 258-265
15. Opitz O.G., Suliman Y., Hahn W.C., et al. Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest 108 (2001) 725-732
16. Bodnar A.G., Ouellette M., Frolkis M., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 279 (1998) 349-352
17. Zhu J., Wang H., Bishop J.M., et al. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci U S A 96 (1999) 3723-3728
18. Choudhury A.R., Ju Z., Djojosubroto M.W., et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet 39 (2007) 99-105
19. Jiang H., Ju Z., and Rudolph K.L. Telomere shortening and ageing. Z Gerontol Geriatr 40 (2007) 314-324
20. Vaziri H., Dragowska W., Allsopp R.C., et al. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci U S A 91 (1994) 9857-9860
21. Allsopp R.C., Morin G.B., DePinho R., et al. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 102 (2003) 517-520
22. Sarin K.Y., Cheung P., Gilison D., et al. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436 (2005) 1048-1052
23. O'Sullivan J., Risques R.A., Mandelson M.T., et al. Telomere length in the colon declines with age: a relation to colorectal cancer?. Cancer Epidemiol Biomarkers Prev 15 (2006) 573-577
24. Blasco M.A., Lee H.W., Hande M.P., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91 (1997) 25-34
25. Ducray C., Pommier J.P., Martins L., et al. Telomere dynamics, end-to-end fusions and telomerase activation during the human fibroblast immortalization process. Oncogene 18 (1999) 4211-4223
26. Rudolph K.L., Millard M., Bosenberg M.W., et al. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28 (2001) 155-159
27. DePinho R.A. The age of cancer. Nature 408 (2000) 248-254
28. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
29. Artandi S.E., Chang S., Lee S.L., et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406 (2000) 641-645
30. Farazi P.A., Glickman J., Jiang S., et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 63 (2003) 5021-5027
31. Rudolph K.L., Chang S., Lee H.W., et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96 (1999) 701-712
32. Lechel A., Holstege H., Begus Y., et al. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 132 (2007) 1465-1475
33. Livstone E.M., Sheahan D.G., and Behar J. Studies of esophageal epithelial cell proliferation in patients with reflux esophagitis. Gastroenterology 73 (1977) 1315-1319
34. Zhang F., Altorki N.K., Wu Y.C., et al. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 121 (2001) 1391-1399
35. Olliver J.R., Hardie L.J., Dexter S., et al. DNA damage levels are raised in Barrett's oesophageal mucosa relative to the squamous epithelium of the oesophagus. Biomarkers 8 (2003) 509-521
36. Theisen J., Peters J.H., Fein M., et al. The mutagenic potential of duodenoesophageal reflux. Ann Surg 241 (2005) 63-68
37. Wetscher G.J., Hinder R.A., Bagchi D., et al. Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am J Surg 170 (1995) 552-556 discussion 556-557
38. Souza R.F., Lunsford T., Ramirez R.D., et al. GERD is associated with shortened telomeres in the squamous epithelium of the distal esophagus. Am J Physiol Gastrointest Liver Physiol 293 (2007) G19-G24
39. Winters Jr. C., Spurling T.J., Chobanian S.J., et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 92 (1987) 118-124
40. Jankowski J.A., Wright N.A., Meltzer S.J., et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 154 (1999) 965-973
41. Rabinovitch P.S., Longton G., Blount P.L., et al. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 96 (2001) 3071-3083
42. Reid B.J., Blount P.L., and Rabinovitch P.S. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 13 (2003) 369-397
43. Reid B.J., Prevo L.J., Galipeau P.C., et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96 (2001) 2839-2848
44. Wong D.J., Paulson T.G., Prevo L.J., et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 61 (2001) 8284-8289
45. Barrett M.T., Sanchez C.A., Prevo L.J., et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22 (1999) 106-109
46. Meeker A.K., Hicks J.L., Iacobuzio-Donahue C.A., et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 10 (2004) 3317-3326
47. Goessel G., Quante M., Hahn W.C., et al. Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci U S A 102 (2005) 15599-15604
48. Delhaye M., Louis H., Degraef C., et al. Relationship between hepatocyte proliferative activity and liver functional reserve in human cirrhosis. Hepatology 23 (1996) 1003-1011
49. Wiemann S.U., Satyanarayana A., Tsahuridu M., et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 16 (2002) 935-942
50. Rudolph K.L., Chang S., Millard M., et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 287 (2000) 1253-1258
51. Satyanarayana A., Wiemann S.U., Buer J., et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. Embo J 22 (2003) 4003-4013
52. Lunz III J.G., Tsuji H., Nozaki I., et al. An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology 41 (2005) 1262-1271
53. Krizhanovsky V., Yon M., Dickins R.A., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 134 (2008) 657-667
54. Plentz R.R., Park Y.N., Lechel A., et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 45 (2007) 968-976
55. Plentz R.R., Schlegelberger B., Flemming P., et al. Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. Hepatology 42 (2005) 522-526
56. Plentz R.R., Caselitz M., Bleck J.S., et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 40 (2004) 80-86
57. O'Sullivan J.N., Bronner M.P., Brentnall T.A., et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 32 (2002) 280-284
58. Risques R.A., Lai L.A., Brentnall T.A., et al. Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology 135 (2008) 410-418
59. Cottliar A., Fundia A., Boerr L., et al. High frequencies of telomeric associations, chromosome aberrations, and sister chromatid exchanges in ulcerative colitis. Am J Gastroenterol 95 (2000) 2301-2307
60. von Zglinicki T., and Martin-Ruiz C.M. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 5 (2005) 197-203
61. Bekaert S., De Meyer T., Rietzschel E.R., et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell 6 (2007) 639-647
62. Risques R.A., Vaughan T.L., Li X., et al. Leukocyte telomere length predicts cancer risk in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 16 (2007) 2649-2655
63. Hiyama E., Kodama T., Shinbara K., et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res 57 (1997) 326-331
64. van Heek N.T., Meeker A.K., Kern S.E., et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 161 (2002) 1541-1547
65. Dikmen Z.G., Gellert G.C., Jackson S., et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 65 (2005) 7866-7873
66. Djojosubroto M.W., Chin A.C., Go N., et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 42 (2005) 1127-1136
67. Gellert G.C., Dikmen Z.G., Wright W.E., et al. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 96 (2006) 73-81
68. Hochreiter A.E., Xiao H., Goldblatt E.M., et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 12 (2006) 3184-3192
69. Wang E.S., Wu K., Chin A.C., et al. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103 (2004) 258-266
70. Harley C.B. Telomerase and cancer therapeutics. Nat Rev Cancer 8 (2008) 167-179
71. Parkhurst M.R., Riley J.P., Igarashi T., et al. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10 (2004) 4688-4698
72. Vonderheide R.H., Domchek S.M., Schultze J.L., et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10 (2004) 828-839
73. Bernhardt S.L., Gjertsen M.K., Trachsel S., et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 95 (2006) 1474-1482
74. Brunsvig P.F., Aamdal S., Gjertsen M.K., et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55 (2006) 1553-1564
75. Djojosubroto M.W., Choi Y.S., Lee H.W., et al. Telomeres and telomerase in aging, regeneration and cancer. Mol Cells 15 (2003) 164-175
76. Rabinovitch P.S., Dziadon S., Brentnall T.A., et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res 59 (1999) 5148-5153
77. Wu X., Amos C.I., Zhu Y., et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 95 (2003) 1211-1218
78. Meyerson M. Role of telomerase in normal and cancer cells. J Clin Oncol 18 (2000) 2626-2634